Company intelligence / Profile preview
Ellipses Pharma
London, England, United Kingdomellipses.life ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Preliminary results from ongoing Phase 1/2 studies of EP0042 show favorable safety and initial efficacy in AML. EP0057 has orphan drug designation and is being evaluated in phase 2 studies for advanced ovarian cancer with olaparib. The company recently announced the development of a next-generation immuno-oncology checkpoint inhibitor.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (e.g., kinase inhibitors)Nanoparticle drug conjugatesImmuno-oncology agents (checkpoint inhibitors)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Collaborations with global key opinion leaders via its Scientific Affairs Group to guide asset selection and trial design.
Beyond the preview
Go deeper on Ellipses Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ellipses Pharma.